Dj Amphenol Blows Past Earnings Estimates. The Stock Sinks 11%. - Barrons.Com

Investing.com -- Meta Platforms Inc (NASDAQ:META) stock is climbing ahead of its earnings report on Wednesday as several major Wall Street research firms maintain positive ratings despite worries about increased spending on artificial intelligence technology.

Four prominent Wall Street firms have reaffirmed bullish stances on Meta with price targets between $800 and $870. Wolfe Research kept its Outperform rating with an $800 target, forecasting 21% year-over-year revenue growth in 2026, exceeding the Street’s 18.5% estimate. The firm also expects higher capital expenditures of $118 billion compared to consensus estimates of around $110 billion.

Bernstein maintained its Outperform rating with an $870 target, emphasizing Meta’s strong product deployment capabilities while recognizing investor concerns about increased AI investment. The firm pointed out that Meta AI already has over 1 billion monthly users even with "average" models, suggesting substantial growth potential with improved AI technology.

Bank of America Securities continued its Buy rating with an $810 price target. The firm expects fourth-quarter revenue of $59.2 billion and earnings per share of $8.27, both above consensus estimates. Their research suggests potential upside driven by healthy macroeconomic conditions, usage growth, and AI-enhanced ad targeting.

Raymond James reaffirmed its Strong Buy rating with an $800 target, projecting 20% and 19% top-line growth in 2026 and 2027, respectively, compared to Street estimates of 18% and 16%. The firm described Meta as an "AI Tweener" that could see its narrative change rapidly with breakthroughs in its Llama model or increased AI monetization, though near-term concerns persist about higher expenses and capital expenditures.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Investing.com -- Odysight.ai Inc. (NASDAQ:ODYS) stock rose 6.9% Wednesday after the AI-based monitoring solutions provider announced it received two pilot orders from a major defense customer for monitoring applications on aerial platforms.

The first order involves integrating and evaluating a computer-vision-based monitoring system on an operational combat helicopter, while the second focuses on monitoring a critical component within an airborne weapons system.

"These pilot orders from this Major Defense Customer represent an important step in the evaluation and validation of our monitoring solutions within complex aeronautical environments," said Yehu Ofer, Chief Executive Officer of Odysight.ai.

The company indicated that successful pilot programs could lead to broader operational deployment. The first order includes integration design, installation surveys, supply of integration kits, system installation, testing, and flight trials. The second order encompasses an initial laboratory demonstration, a functional separation test, and data collection to evaluate predictive maintenance capabilities.

Odysight.ai develops AI-based monitoring and Predictive Maintenance solutions, and the company believes these orders reflect growing interest in advanced monitoring systems within defense and aeronautics sectors as part of a shift toward data-driven maintenance approaches.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Investing.com -- The Republican chair of a U.S. House committee is examining Ford’s plan to repurpose its U.S. battery manufacturing facilities to produce lithium iron phosphate cells and grid-scale energy storage systems using technology licensed from China’s CATL.

Representative John Moolenaar expressed concerns about Ford’s strategy in a letter to CEO Jim Farley. "Ford’s revised business plan raises important questions about whether the original licensing terms have been updated, expanded, or otherwise altered to accommodate the company’s new focus on energy storage systems and data center markets," Moolenaar wrote.

The congressman has requested Ford to answer a series of questions regarding its arrangement with CATL. The inquiry focuses on the automaker’s decision to repurpose existing U.S. battery manufacturing facilities for the production of these specialized battery cells.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Investing.com -- Solid Power Inc (NASDAQ:SLDP) stock fell 6.6% Wednesday after the solid-state battery technology developer announced a registered direct offering expected to raise approximately $130 million in gross proceeds.

The Colorado-based company has entered into a securities purchase agreement with a single sector-focused institutional investor for the sale of 17 million shares of common stock, pre-funded warrants to purchase 5.8 million shares, and common warrants to purchase up to 45.6 million shares.

The offering is priced at $5.70 per share of common stock with accompanying warrants, and $5.699 per pre-funded warrant with accompanying warrants. The common warrants will be immediately exercisable at $7.25 per share and will expire 7 years from issuance.

Solid Power intends to use the proceeds for working capital and general corporate purposes in its development of next-generation batteries. The company reported approximately $336.5 million in total liquidity as of December 31, 2025.

J.P. Morgan Securities LLC and A.G.P./Alliance Global Partners are serving as placement agents for the offering, which is expected to close around January 29, 2026, subject to customary closing conditions.

As of December 31, 2025, Solid Power had approximately 201.2 million shares of common stock outstanding.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Investing.com -- AlphaTON Capital Corp. (NASDAQ:ATON) stock jumped 19.6% on Wednesday after the company announced its leadership team presented at President Donald Trump’s Mar-a-Lago Club in Palm Beach, Florida.

The private, invitation-only investor gathering on January 27, 2026, brought together high-net-worth investors, family offices, and strategic capital partners. During the presentation, AlphaTON shared insights into its infrastructure expansion initiatives, strategic acquisitions, and growth strategy within the TON blockchain ecosystem.

AlphaTON positions itself as a public-market gateway to the TON ecosystem, which leverages Telegram’s global user base. The company builds TON-based infrastructure, operates validator systems, manages a TON token reserve, and invests in decentralized applications across finance, gaming, and digital commerce.

The company recently raised net $44 million in capital and is generating revenue from AI infrastructure deployments. AlphaTON closed a $15 million registered direct offering at $1.00 per share and initiated a $46 million investment in AI infrastructure expansion, including 576 NVIDIA B300 chips scheduled for delivery in March 2026.

"Our mission is to build the infrastructure and applications that will power the next generation of the digital economy," said Enzo Villani, Executive Chairman and CIO of AlphaTON Capital. "Presenting at President Trump’s Mar-a-Lago Club allowed us to engage directly with a sophisticated group of investors who recognize the scale and momentum of the TON ecosystem."

The company has also established strategic partnerships, including becoming a Founding Federated Node Architecture Provider for privacy-preserving AI through an agreement with Midnight Foundation, which generates monthly revenue.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Investing.com -- OKYO Pharma Limited (NASDAQ:OKYO) stock climbed 4.7% Wednesday after the company announced successful discussions with the FDA regarding its Phase 2b/3 clinical trial design for urcosimod, a treatment for neuropathic corneal pain (NCP).

The London and New York-based biopharmaceutical company received confirmation from the FDA that its proposed primary endpoint of Visual Analogue Scale pain reduction at Week 12 is clinically meaningful. The agency specifically acknowledged that a 2-point or greater improvement on the VAS scale represents a meaningful treatment effect.

The FDA also endorsed OKYO’s proposed study design, sample size, and powering assumptions, while agreeing that the Ocular Pain Assessment Survey is appropriate as supportive quality-of-life evidence. Additionally, the agency aligned with the company’s Chemistry, Manufacturing and Controls strategy.

"This alignment represents an important step forward and underscores the potential to address a significant unmet medical need in patients with neuropathic corneal pain," said Raj Patil, Chief Scientific Officer at OKYO Pharma.

The company plans to initiate a 120-patient Phase 2b/3 multiple-dose study of urcosimod to treat NCP in the first half of this year. Urcosimod previously received fast track designation from the FDA and was granted the first Investigational New Drug application to treat patients with NCP.

OKYO Pharma focuses on developing therapies for the treatment of neuropathic corneal pain and inflammatory eye diseases.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.